Details of the Drug

General Information of Drug (ID: DM6I5GR)

Drug Name
Promethazine
Synonyms
Antiallersin; Aprobit; Avomine; Camergan; Dimapp; Diphergan; Diprazin; Diprazine; Diprozin; Fargan; Fenazil; Fenetazina; Fenetazine; Genphen; Hiberna; Histargan; Iergigan; Isophenergan; Isopromethazine; Lercigan; Lergigan; Metaryl; Pelpica; Phargan; Phenargan; Phenerzine; Phensedyl; Pilothia; Pilpophen; Pipolphene; Proazaimine; Proazamine; Procit; Promacot; Promazinamide; Promergan; Promesan; Prometasin; Prometazin; Prometazina; Prometazine; Prometh; Promethacon; Promethaine; Promethazin; PromethazineHcl; Promethazinum; Promethegan; Promethiazine; Promezathine; Prorex; Protazine; Prothazin; Prothazine; Provigan; Pyrethia; Pyrethiazine; Remsed; Romergan; Rumergan; Tanidil; Thiergan; Valergine; Vallergine; Lilly 01516; Lilly 1516; RP 3277; SKF 1498; WY 509; A-91033; Atosil (TN); Avomine (TN); Fargan (TN); Farganesse (TN); Lergigan (TN); Phenergan (TN); Phenoject-50; Pro-50; Prometazina [INN-Spanish]; Promethazine [INN:BAN]; Promethazinum [INN-Latin]; Promethegan (TN); Prothiazine (TN); Receptozine (TN); Romergan (TN); Zipan-25; Dimethylamino-isopropyl-phenthiazin; Dimethylamino-isopropyl-phenthiazin [German]; Promethazine (JAN/INN)
Indication
Disease Entry ICD 11 Status REF
Nausea MD90 Approved [1], [2]
Therapeutic Class
Antiallergic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 284.4
Topological Polar Surface Area (xlogp) 4.8
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [4]
Elimination
2% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 14 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.03281 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.09% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 14 L/kg [4]
Chemical Identifiers
Formula
C17H20N2S
IUPAC Name
N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
Canonical SMILES
CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C
InChI
InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3
InChIKey
PWWVAXIEGOYWEE-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4927
ChEBI ID
CHEBI:8461
CAS Number
60-87-7
DrugBank ID
DB01069
TTD ID
D0T2XU
VARIDT ID
DR00674
INTEDE ID
DR1353
ACDINA ID
D00561

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H1 receptor (H1R) TTTIBOJ HRH1_HUMAN Antagonist [6], [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [8]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Nausea
ICD Disease Classification MD90
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Histamine H1 receptor (H1R) DTT HRH1 6.74E-01 0.13 0.43
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 4.32E-01 4.39E-02 4.30E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 8.70E-01 2.98E-02 1.22E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Promethazine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Rolapitant DM8XP26 Moderate Decreased metabolism of Promethazine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [37]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Promethazine and Cyclizine. Nausea/vomiting [MD90] [38]
Metoclopramide DMFA5MY Major Additive antidopaminergic effects by the combination of Promethazine and Metoclopramide. Nausea/vomiting [MD90] [39]
Coadministration of a Drug Treating the Disease Different from Promethazine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Promethazine and Ivosidenib. Acute myeloid leukaemia [2A60] [40]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Promethazine and Midostaurin. Acute myeloid leukaemia [2A60] [41]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Promethazine and Idarubicin. Acute myeloid leukaemia [2A60] [41]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Promethazine and Arn-509. Acute myeloid leukaemia [2A60] [42]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Promethazine and Gilteritinib. Acute myeloid leukaemia [2A60] [43]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Promethazine and Oliceridine. Acute pain [MG31] [41]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Promethazine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [44]
Trimethaphan DMHF4IQ Moderate Additive hypotensive effects by the combination of Promethazine and Trimethaphan. Aneurysm/dissection [BD50] [45]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Promethazine and Ivabradine. Angina pectoris [BA40] [42]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Promethazine and Bepridil. Angina pectoris [BA40] [41]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Promethazine and Dronedarone. Angina pectoris [BA40] [41]
Nifedipine DMSVOZT Moderate Additive hypotensive effects by the combination of Promethazine and Nifedipine. Angina pectoris [BA40] [46]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Promethazine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [47]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Promethazine and Cilostazol. Arterial occlusive disease [BD40] [41]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Promethazine and Posaconazole. Aspergillosis [1F20] [41]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Promethazine and Levalbuterol. Asthma [CA23] [48]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Promethazine and Pirbuterol. Asthma [CA23] [49]
Ephedrine DMMV0KW Moderate Antagonize the effect of Promethazine when combined with Ephedrine. Asthma [CA23] [50]
Lisdexamfetamine DM6W8V5 Moderate Antagonize the effect of Promethazine when combined with Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [50]
Desipramine DMT2FDC Moderate Increased plasma concentrations of Promethazine and Desipramine due to competitive inhibition of the same metabolic pathway. Attention deficit hyperactivity disorder [6A05] [51]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Promethazine and Ofloxacin. Bacterial infection [1A00-1C4Z] [52]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Promethazine and Clarithromycin. Bacterial infection [1A00-1C4Z] [41]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Promethazine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [52]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Promethazine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [52]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Promethazine and Levofloxacin. Bacterial infection [1A00-1C4Z] [52]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Promethazine and Retigabine. Behcet disease [4A62] [41]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Promethazine and Cariprazine. Bipolar disorder [6A60] [38]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Promethazine and Eribulin. Breast cancer [2C60-2C6Y] [41]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Promethazine and Lapatinib. Breast cancer [2C60-2C6Y] [41]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Promethazine when combined with Acetylcholine. Cataract [9B10] [53]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Promethazine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [54]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Promethazine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [55]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Promethazine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [49]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Promethazine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [48]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Promethazine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [55]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Promethazine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [55]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Promethazine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [49]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Promethazine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [49]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Promethazine and Halothane. Corneal disease [9A76-9A78] [41]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Promethazine and Sevoflurane. Corneal disease [9A76-9A78] [41]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Promethazine and Probucol. Coronary atherosclerosis [BA80] [41]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Promethazine and Pasireotide. Cushing syndrome [5A70] [41]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Promethazine and Osilodrostat. Cushing syndrome [5A70] [42]
Cyclandelate DMO0R76 Moderate Additive hypotensive effects by the combination of Promethazine and Cyclandelate. Dementia [6D80-6D8Z] [46]
Isocarboxazid DMAF1NB Moderate Additive hypotensive effects by the combination of Promethazine and Isocarboxazid. Depression [6A70-6A7Z] [56]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Promethazine and Escitalopram. Depression [6A70-6A7Z] [57]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Promethazine and OPC-34712. Depression [6A70-6A7Z] [38]
Clomipramine DMINRKW Moderate Increased plasma concentrations of Promethazine and Clomipramine due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [51]
Doxepin DMPI98T Moderate Increased plasma concentrations of Promethazine and Doxepin due to competitive inhibition of the same metabolic pathway. Depression [6A70-6A7Z] [51]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Promethazine and Esketamine. Depression [6A70-6A7Z] [58]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Promethazine and Mepenzolate. Digestive system disease [DE2Z] [38]
Tetrabenazine DMYWQ0O Major Additive antidopaminergic effects by the combination of Promethazine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [59]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Promethazine and Deutetrabenazine. Dystonic disorder [8A02] [60]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Promethazine and Ingrezza. Dystonic disorder [8A02] [61]
Stiripentol DMMSDOY Moderate Decreased metabolism of Promethazine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [62]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Promethazine and Diphenhydramine. Episodic vestibular syndrome [AB31] [38]
Nadolol DMW6GVL Moderate Additive hypotensive effects by the combination of Promethazine and Nadolol. Essential hypertension [BA00] [46]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Promethazine and Solifenacin. Functional bladder disorder [GC50] [38]
Mirabegron DMS1GYT Moderate Decreased metabolism of Promethazine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [63]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Promethazine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [41]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Promethazine when combined with Pilocarpine. Glaucoma [9C61] [53]
Carvedilol DMHTEAO Moderate Additive hypotensive effects by the combination of Promethazine and Carvedilol. Heart failure [BD10-BD1Z] [46]
Procarbazine DMIK367 Moderate Additive CNS depression effects by the combination of Promethazine and Procarbazine. Hodgkin lymphoma [2B30] [56]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Promethazine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Promethazine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [65]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Promethazine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [41]
Acebutolol DM0TI4U Moderate Additive hypotensive effects by the combination of Promethazine and Acebutolol. Hypertension [BA00-BA04] [46]
Captopril DM458UM Moderate Additive hypotensive effects by the combination of Promethazine and Captopril. Hypertension [BA00-BA04] [46]
Penbutolol DM4ES8F Moderate Additive hypotensive effects by the combination of Promethazine and Penbutolol. Hypertension [BA00-BA04] [46]
Nebivolol DM7F1PA Moderate Additive hypotensive effects by the combination of Promethazine and Nebivolol. Hypertension [BA00-BA04] [46]
Levamlodipine DM92S6N Moderate Additive hypotensive effects by the combination of Promethazine and Levamlodipine. Hypertension [BA00-BA04] [46]
TAK-491 DMCF6SX Moderate Additive hypotensive effects by the combination of Promethazine and TAK-491. Hypertension [BA00-BA04] [46]
Diazoxide DML1538 Moderate Additive hypotensive effects by the combination of Promethazine and Diazoxide. Hypertension [BA00-BA04] [46]
Deserpidine DMRH7CV Moderate Additive hypotensive effects by the combination of Promethazine and Deserpidine. Hypertension [BA00-BA04] [46]
Hydralazine DMU8JGH Moderate Additive hypotensive effects by the combination of Promethazine and Hydralazine. Hypertension [BA00-BA04] [46]
Clevidipine butyrate DMW4M97 Moderate Additive hypotensive effects by the combination of Promethazine and Clevidipine butyrate. Hypertension [BA00-BA04] [46]
Givosiran DM5PFIJ Moderate Decreased metabolism of Promethazine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [66]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Promethazine and Belladonna. Infectious gastroenteritis/colitis [1A40] [38]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Promethazine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [67]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Promethazine and ITI-007. Insomnia [7A00-7A0Z] [38]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Promethazine and Polyethylene glycol. Irritable bowel syndrome [DD91] [41]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Promethazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [42]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Promethazine and Crizotinib. Lung cancer [2C25] [68]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Promethazine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [69]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Promethazine and Osimertinib. Lung cancer [2C25] [70]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Promethazine and Lumefantrine. Malaria [1F40-1F45] [58]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Promethazine and Halofantrine. Malaria [1F40-1F45] [71]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Promethazine and Hydroxychloroquine. Malaria [1F40-1F45] [72]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Promethazine and Primaquine. Malaria [1F40-1F45] [41]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Promethazine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [42]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Promethazine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [73]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Promethazine and Vemurafenib. Melanoma [2C30] [41]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Promethazine and LGX818. Melanoma [2C30] [74]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Promethazine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [75]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Promethazine and Lasmiditan. Migraine [8A80] [76]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Promethazine and Flibanserin. Mood disorder [6A60-6E23] [77]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Promethazine and Panobinostat. Multiple myeloma [2A83] [78]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Promethazine and Siponimod. Multiple sclerosis [8A40] [58]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Promethazine and Fingolimod. Multiple sclerosis [8A40] [41]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Promethazine and Ozanimod. Multiple sclerosis [8A40] [79]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Promethazine and Romidepsin. Mycosis fungoides [2B01] [41]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Promethazine caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [42]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Promethazine and Nilotinib. Myeloproliferative neoplasm [2A20] [41]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Promethazine and Dasatinib. Myeloproliferative neoplasm [2A20] [80]
Dextroamphetamine DMMIHVP Moderate Antagonize the effect of Promethazine when combined with Dextroamphetamine. Narcolepsy [7A20] [50]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Promethazine and Phenindamine. Nasopharyngitis [CA00] [38]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Promethazine and Bupropion. Nicotine use disorder [6C4A] [41]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Promethazine and Entrectinib. Non-small cell lung cancer [2C25] [58]
Phendimetrazine DM6TS1N Moderate Antagonize the effect of Promethazine when combined with Phendimetrazine. Obesity [5B80-5B81] [50]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Promethazine caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [81]
Polythiazide DMCH80F Moderate Additive hypotensive effects by the combination of Promethazine and Polythiazide. Oedema [MG29] [46]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Promethazine and Levomethadyl Acetate. Opioid use disorder [6C43] [42]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Promethazine and Lofexidine. Opioid use disorder [6C43] [41]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Promethazine and Rucaparib. Ovarian cancer [2C73] [41]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Promethazine and Flavoxate. Pain [MG30-MG3Z] [38]
Methamphetamine DMPM4SK Moderate Antagonize the effect of Promethazine when combined with Methamphetamine. Pain [MG30-MG3Z] [82]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Promethazine and Triclabendazole. Parasitic worm infestation [1F90] [41]
Safinamide DM0YWJC Moderate Additive hypotensive effects by the combination of Promethazine and Safinamide. Parkinsonism [8A00] [56]
Pergolide DM14MAE Moderate Antagonize the effect of Promethazine when combined with Pergolide. Parkinsonism [8A00] [83]
Opicapone DM1BKA6 Moderate Antagonize the effect of Promethazine when combined with Opicapone. Parkinsonism [8A00] [83]
Rasagiline DM3WKQ4 Moderate Additive CNS depression effects by the combination of Promethazine and Rasagiline. Parkinsonism [8A00] [56]
Levodopa DMN3E57 Moderate Additive hypotensive effects by the combination of Promethazine and Levodopa. Parkinsonism [8A00] [83]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Promethazine and Pimavanserin. Parkinsonism [8A00] [84]
Bromocriptine DMVE3TK Moderate Additive CNS depression effects by the combination of Promethazine and Bromocriptine. Parkinsonism [8A00] [83]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Promethazine and Orphenadrine. Parkinsonism [8A00] [38]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Promethazine and Methylscopolamine. Peptic ulcer [DA61] [38]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Promethazine and Macimorelin. Pituitary gland disorder [5A60-5A61] [85]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Promethazine and Lefamulin. Pneumonia [CA40] [86]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Promethazine and Degarelix. Prostate cancer [2C82] [42]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Promethazine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [87]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Promethazine and Enzalutamide. Prostate cancer [2C82] [42]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Promethazine and Relugolix. Prostate cancer [2C82] [42]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Promethazine and Bicalutamide. Prostate cancer [2C82] [42]
Terazosin DM3JCVS Moderate Additive hypotensive effects by the combination of Promethazine and Terazosin. Prostate hyperplasia [GA90] [46]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Promethazine and Silodosin. Prostate hyperplasia [GA90] [46]
Levomepromazine DMIKFEL Moderate Additive anticholinergic effects by the combination of Promethazine and Levomepromazine. Psychotic disorder [6A20-6A25] [38]
Neupro DMHEAB1 Moderate Additive hypotensive effects by the combination of Promethazine and Neupro. Restless legs syndrome [7A80] [83]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Promethazine and Quetiapine. Schizophrenia [6A20] [41]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Promethazine and Aripiprazole. Schizophrenia [6A20] [38]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Promethazine and Iloperidone. Schizophrenia [6A20] [41]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Promethazine and Paliperidone. Schizophrenia [6A20] [41]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Promethazine and Molindone. Schizophrenia [6A20] [38]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Promethazine and Thiothixene. Schizophrenia [6A20] [38]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Promethazine and Amisulpride. Schizophrenia [6A20] [88]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Promethazine and Asenapine. Schizophrenia [6A20] [41]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Promethazine and Pimozide. Schizophrenia [6A20] [42]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Promethazine and LEE011. Solid tumour/cancer [2A00-2F9Z] [41]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Promethazine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [41]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Promethazine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [42]
Pitolisant DM8RFNJ Moderate Decreased metabolism of Promethazine caused by Pitolisant mediated inhibition of CYP450 enzyme. Somnolence [MG42] [42]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Promethazine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [41]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Promethazine and Lenvatinib. Thyroid cancer [2D10] [41]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Promethazine and Cabozantinib. Thyroid cancer [2D10] [42]
Papaverine DMCA9QP Moderate Additive hypotensive effects by the combination of Promethazine and Papaverine. Tonus and reflex abnormality [MB47] [46]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Promethazine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [38]
Trimeprazine DMEMV9D Moderate Additive anticholinergic effects by the combination of Promethazine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [44]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Promethazine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [38]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Promethazine and Propafenone. Ventricular tachyarrhythmia [BC71] [41]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Promethazine and Flecainide. Ventricular tachyarrhythmia [BC71] [41]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Promethazine and Amiodarone. Ventricular tachyarrhythmia [BC71] [41]
⏷ Show the Full List of 160 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 27 E00381 83511 Colorant
D&C red no. 30 E00456 3000709 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Edetate disodium E00186 8759 Complexing agent
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Promethazine 50 mg tablet 50 mg Oral Tablet Oral
Promethazine 25 mg tablet 25 mg Oral Tablet Oral
Promethazine 12.5 mg tablet 12.5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7282).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 089013.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J Pharmacol Sci. 2008 May;107(1):66-79.
7 Inhibition by histamine H1 receptor antagonists of endogenous glibenclamide-sensitive K+ channels in follicle-enclosed Xenopus oocytes. Eur J Pharmacol. 1994 Jan 1;266(1):99-102.
8 Akathisia with combined use of midodrine and promethazine. JAMA. 2006 May 3;295(17):2000-1. Letter
9 Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003 Oct;13(10):619-26.
10 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
11 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
12 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
13 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
14 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
15 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
16 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
17 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
18 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
19 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
20 Effect of tamoxifen on the enzymatic activity of human cytochrome CYP2B6. J Pharmacol Exp Ther. 2002 Jun;301(3):945-52.
21 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
22 Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999 Sep 1;58(5):787-96.
23 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
24 Insights into CYP2B6-mediated drug-drug interactions. Acta Pharm Sin B. 2016 Sep;6(5):413-425.
25 Drugs that may have potential CYP2B6 interactions.
26 Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica. 2007 Jul;37(7):717-24.
27 Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone metabolism by cytochrome P450 2B6. Drug Metab Dispos. 2005 Dec;33(12):1760-4.
28 PharmGKB summary: phenytoin pathway. Pharmacogenet Genomics. 2012 Jun;22(6):466-70.
29 Application of the relative activity factor approach in scaling from heterologously expressed cytochromes p450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001 Apr;297(1):326-37.
30 Cloning and pharmacological characterization of a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol. 2001 Mar;59(3):420-6.
31 Clinical research of Ibudilast on treating the steroid resistant allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jan;23(2):63-6.
32 Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy. Curr Allergy Asthma Rep. 2009 Mar;9(2):140-8.
33 Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med. 2002 Jun;73(6):570-4.
34 Novel therapeutic usage of low-dose doxepin hydrochloride. Expert Opin Investig Drugs. 2007 Aug;16(8):1295-305.
35 Influence of epinastine hydrochloride, an H1-receptor antagonist, on the function of mite allergen-pulsed murine bone marrow-derived dendritic cell... Mediators Inflamm. 2009;2009:738038.
36 Examining the tolerability of the non-sedating antihistamine desloratadine: a prescription-event monitoring study in England. Drug Saf. 2009;32(2):169-79.
37 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
38 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
39 Bateman DN, Rawlins MD, Simpson JM "Extrapyramidal reactions with metoclopramide." Br Med J (Clin Res Ed) 291 (1985): 930-2. [PMID: 3929968]
40 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
41 Canadian Pharmacists Association.
42 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
43 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
44 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
45 Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
46 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
47 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
48 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
49 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
50 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
51 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
52 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
53 Multum Information Services, Inc. Expert Review Panel.
54 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
55 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
56 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
57 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
58 Cerner Multum, Inc. "Australian Product Information.".
59 Burke RE, Fahn S, Mayeux R, Weinberg H, Louis K, Willner JH "Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease." Neurology 31 (1981): 1022-5. [PMID: 6115336]
60 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
61 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
62 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
63 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
64 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
65 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
66 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
67 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
68 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
69 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
70 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
71 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
72 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
73 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
74 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
75 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
76 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
77 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
78 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
79 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
80 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
81 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
82 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]
83 Mims RB, Scott CL, Modebe O, Bethune JE "Inhibition of L-dopa-induced growth hormone stimulation by pyridoxine and chlorpromazine." J Clin Endocrinol Metab 40 (1975): 256-9. [PMID: 1117978]
84 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
85 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
86 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
87 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
88 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.